| 4.75 -0.15 (-3.06%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.84 | 1-year : | 6.82 |
| Resists | First : | 5 | Second : | 5.84 |
| Pivot price | 4.58  |
|||
| Supports | First : | 4.13 |
Second : | 3.59 |
| MAs | MA(5) : | 4.85  |
MA(20) : | 4.44 |
| MA(100) : | 5.27 |
MA(250) : | 7.4 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 84.9 |
D(3) : | 87.8 |
| RSI | RSI(14): 59.4 |
|||
| 52-week | High : | 43.5 | Low : | 3.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INTS ] has closed below upper band by 38.0%. Bollinger Bands are 13.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.81 - 4.83 | 4.83 - 4.85 |
| Low: | 4.5 - 4.53 | 4.53 - 4.56 |
| Close: | 4.7 - 4.74 | 4.74 - 4.79 |
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Wed, 15 Jul 2026
Intensity Therapeutics (INTS) AGM 2026 Summary - Quartr
Wed, 15 Jul 2026
Intensity Therapeutics (INTS) Q4 2025 earnings summary - Quartr
Wed, 15 Jul 2026
Intensity Therapeutics restarts 61-patient breast cancer trial - grafa.com
Wed, 15 Jul 2026
Intensity Therapeutics resumes patient dosing in Swiss trial - Investing.com
Tue, 14 Jul 2026
Why Did INTS Stock Plummet 25% Today? - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 126 (K) |
| Shares Short P.Month | 75 (K) |
| EPS | -4.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -90.4 % |
| Return on Equity (ttm) | -207.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.19 |
| PEG Ratio | 0 |
| Price to Book value | 1.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|